Foti Giovanni, Longo Chiara, Faccioli Niccolò, Guerriero Massimo, Stefanini Flavio, Buonfrate Dora
Radiology Department, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.
Radiology Department, Verona University Hospital, 37129 Verona, Italy.
Diagnostics (Basel). 2023 Mar 22;13(6):1201. doi: 10.3390/diagnostics13061201.
Dual-energy computed tomography (DECT) has been used for detecting pulmonary embolism, but the role of lung perfusion DECT as a predictor of prognosis of coronavirus disease 2019 (COVID-19) has not been defined yet. The aim of our study was to explore whether the enhancement pattern in COVID-19+ patients relates to the disease outcome. A secondary aim was to compare the lung volumes in two subgroups of patients. In this observational study, we considered all consecutive COVID-19+ patients who presented to the emergency room between January 2021 and December 2021 with respiratory symptoms (with mild to absent lung consolidation) and were studied by chest contrast-enhanced DECT to be eligible. Two experienced radiologists post-processed the images using the "lung-analysis" software (SyngoVia). Absolute and relative enhancement lung volumes were assessed. Patients were stratified in two subgroups depending on clinical outcome at 30 days: (i) good outcome (i.e., discharge, absence of clinical or imaging signs of disease); (ii) bad outcome (i.e., hospitalization, death). Patient sub-groups were compared using chi-square test or Fisher test for qualitative parameters, chi-square test or Spearman's Rho test for quantitative parameters, Students' -test for parametric variables and Wilcoxon test for non-parametric variables. We enrolled 78 patients (45M), of whom, 16.7% had good outcomes. We did not observe any significant differences between the two groups, both in terms of the total enhancement evaluation (p = 0.679) and of the relative enhancement (p = 0.918). In contrast, the average lung volume of good outcome patients (mean value of 4262 mL) was significantly larger than that of bad outcome patients (mean value of 3577.8 mL), p = 0.0116. All COVID-19+ patients, with either good or bad outcomes, presented similar enhancement parameters and relative enhancements, underlining no differences in lung perfusion. Conversely, a significant drop in lung volume was identified in the bad outcome subgroup eligible compared to the good outcome subgroup.
双能计算机断层扫描(DECT)已被用于检测肺栓塞,但肺部灌注DECT作为2019冠状病毒病(COVID-19)预后预测指标的作用尚未明确。我们研究的目的是探讨COVID-19阳性患者的强化模式是否与疾病转归相关。第二个目的是比较两组患者亚组的肺容积。在这项观察性研究中,我们认为2021年1月至2021年12月期间因呼吸道症状(肺部实变轻微或无实变)到急诊室就诊且接受胸部对比增强DECT检查的所有连续COVID-19阳性患者符合条件。两名经验丰富的放射科医生使用“肺部分析”软件(SyngoVia)对图像进行后处理。评估绝对和相对强化肺容积。根据30天的临床结局将患者分为两个亚组:(i)良好结局(即出院,无疾病的临床或影像学征象);(ii)不良结局(即住院、死亡)。使用卡方检验或Fisher检验比较患者亚组的定性参数,使用卡方检验或Spearman秩相关检验比较定量参数,使用学生t检验比较参数变量,使用Wilcoxon检验比较非参数变量。我们纳入了78例患者(45例男性),其中16.7%的患者结局良好。在总强化评估(p = 0.679)和相对强化方面(p = 0.918),我们未观察到两组之间有任何显著差异。相比之下,结局良好患者的平均肺容积(平均值为4262 mL)显著大于结局不良患者(平均值为3577.8 mL),p = 0.0116。所有COVID-19阳性患者,无论结局良好或不良,均表现出相似的强化参数和相对强化,表明肺灌注无差异。相反,与结局良好亚组相比,结局不良亚组的肺容积显著下降。